Paul Hastings advised Viking Therapeutics on the offering. Viking Therapeutics, Inc. (Nasdaq: VKTX) executed its underwritten offering of $632.5 million of shares of its common stock....
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here